GENE DIVERGENCE OF ARYL HYDROCARBON RECEPTORS (AHR) IN EARLY VERTEBRATES

早期脊椎动物芳基烃受体(AHR)的基因分歧

基本信息

  • 批准号:
    8167612
  • 负责人:
  • 金额:
    $ 8.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-05-01 至 2011-04-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Adverse health effects from exposure to dioxin-like compounds are in part mediated through activation of aryl hydrocarbon receptors (AHR), induction of genes encoding biotransformation enzymes, and dyregulation of numerous genes outside the toxic response pathway. AHR proteins have non-transcriptional roles in cell physiology in the absence and presence of AHR ligands. Thus, it is difficult to distinguish AHR-dependent toxic response mechanisms from the perturbation of endogenous function of AHR. We study the divergence of function among multiple AHR paralogs in early vertebrates so we may separately test the pleiotropic functions of the single mammalian AHR. Our previous studies support that shark AHR paralogs diverge in function. In the current study, several undergraduate student projects are designed to assess the function of shark receptors in cell physiology, development, and toxic responses to AHR agonists, and to investigate the genomic context of these early vertebrate AHR genes with a BAC library. We aim to develop an effective paradigm to separately test hypotheses about subsets of mammalian AHR gene targets and non-transcriptional AHR protein function. Results from our research will provide information relevant to human physiology, development, and environmental health.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

REBEKA RAND MERSON其他文献

REBEKA RAND MERSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('REBEKA RAND MERSON', 18)}}的其他基金

GENE DIVERGENCE OF ARYL HYDROCARBON RECEPTORS (AHR) IN EARLY VERTEBRATES
早期脊椎动物芳基烃受体(AHR)的基因分歧
  • 批准号:
    8360076
  • 财政年份:
    2011
  • 资助金额:
    $ 8.15万
  • 项目类别:
ROLE PARTITIONING BY ARYL HYDROCARBON RECEPTORS IN CELL REGULATION AND TOXICITY
芳基烃受体在细胞调节和毒性中的作用分配
  • 批准号:
    7960140
  • 财政年份:
    2009
  • 资助金额:
    $ 8.15万
  • 项目类别:
ROLE PARTITIONING BY ARYL HYDROCARBON RECEPTORS (AHR) IN CELL REGULATION AND TOX
芳基烃受体 (AHR) 在细胞调节和毒性中的作用分配
  • 批准号:
    7725155
  • 财政年份:
    2008
  • 资助金额:
    $ 8.15万
  • 项目类别:
ROLE PARTITIONING BY ARYL HYDROCARBON RECEPTORS (AHR) IN CELL REGULATION AND TOX
芳基烃受体 (AHR) 在细胞调节和毒性中的作用分配
  • 批准号:
    7609977
  • 财政年份:
    2007
  • 资助金额:
    $ 8.15万
  • 项目类别:
Aryl hydrocarbon receptor regulation of the cell cycle by chromatin modification
芳烃受体通过染色质修饰调节细胞周期
  • 批准号:
    7096124
  • 财政年份:
    2007
  • 资助金额:
    $ 8.15万
  • 项目类别:
Aryl hydrocarbon receptor regulation of the cell cycle by chromatin modification
芳烃受体通过染色质修饰调节细胞周期
  • 批准号:
    7625926
  • 财政年份:
    2007
  • 资助金额:
    $ 8.15万
  • 项目类别:
Aryl hydrocarbon receptor regulation of the cell cycle by chromatin modification
芳烃受体通过染色质修饰调节细胞周期
  • 批准号:
    7477971
  • 财政年份:
    2007
  • 资助金额:
    $ 8.15万
  • 项目类别:
THE ARYL HYDROCARBON RECEPTOR AND OVARIAN DEVELOPMENT
芳基烃受体与卵巢发育
  • 批准号:
    6524720
  • 财政年份:
    2002
  • 资助金额:
    $ 8.15万
  • 项目类别:
THE ARYL HYDROCARBON RECEPTOR AND OVARIAN DEVELOPMENT
芳基烃受体与卵巢发育
  • 批准号:
    6402601
  • 财政年份:
    2001
  • 资助金额:
    $ 8.15万
  • 项目类别:
THE ARYL HYDROCARBON RECEPTOR AND OVARIAN DEVELOPMENT
芳基烃受体与卵巢发育
  • 批准号:
    6294505
  • 财政年份:
    2000
  • 资助金额:
    $ 8.15万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 8.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 8.15万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 8.15万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 8.15万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 8.15万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 8.15万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 8.15万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 8.15万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 8.15万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 8.15万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了